...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Infectious Diseases and Therapy >Comparing the Outcomes of Ceftaroline Plus Vancomycin or Daptomycin Combination Therapy Versus Monotherapy in Adults with Complicated and Prolonged Methicillin-Resistant Staphylococcus Aureus Bacteremia Initially Treated with Supplemental Ceftaroline
【24h】

Comparing the Outcomes of Ceftaroline Plus Vancomycin or Daptomycin Combination Therapy Versus Monotherapy in Adults with Complicated and Prolonged Methicillin-Resistant Staphylococcus Aureus Bacteremia Initially Treated with Supplemental Ceftaroline

机译：比较Ceftaroline Plus vancomycin或Daptomycin组合治疗与成人单药治疗复杂和延长的甲氧西林耐金黄色葡萄球菌菌血症的结果，最初用辅作治疗

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IntroductionMethicillin-resistant Staphylococcus aureus (MRSA) bacteremia confers considerable morbidity and mortality. Although vancomycin or daptomycin monotherapy is usually curative, prolonged bacteremia necessitating supplemental ceftaroline has occurred. The practice has led to the question of whether to continue with ceftaroline following bacteremia resolution.MethodsAdult patients hospitalized with MRSA bacteremia at the University of Kentucky Medical Center between January 2015 and December 2017 were retrospectively reviewed. Study subjects required supplemental ceftaroline due to 4 or more days of bacteremia despite vancomycin or daptomycin. They additionally had accompanying native valve infective endocarditis, osteomyelitis, or brain abscess. Patients were divided into two cohorts. One group continued with ceftaroline plus vancomycin or daptomycin following bacteremia resolution (combination therapy group). The other group received vancomycin or daptomycin alone (monotherapy group). All involved received 6–8?weeks of therapy. Patients’ Pitt bacteremia score (PBS) and Charlson comorbidity index (CCI) values were calculated. Treatment outcomes of inpatient mortality, recurrence of bacteremia, 30-day readmission, acute kidney injury, and leukopenia were recorded and compared.ResultsA total of 30 patients comprised the study population. 15 patients?were assigned to each cohort. The median PBS value of the combination therapy group was 2, compared with 1 among the monotherapy group. The median CCI score of both groups was 0. No statistically significant difference in the aforementioned treatment outcomes was seen between the two groups.ConclusionIn subjects with complicated and prolonged MRSA bacteremia requiring supplemental ceftaroline, clinical outcomes did not differ among patients prescribed vancomycin or daptomycin alone following bacteremia resolution versus patients who continued combination therapy.
机译：推出含胆管抑制金黄色葡萄球菌（MRSA）菌血症赋予了相当大的发病率和死亡率。虽然万古霉素或达摩霉素单疗法通常是治愈的，但延长的菌血症已经发生了需要补充的头孢氨虫。这种做法导致了是否在菌血症决议之后继续伴随着切巴咯啉。在2015年1月至2017年1月在肯塔基州医疗中心大学和2017年12月在2017年12月期间与MRSA菌血症住院的患者。尽管万古霉素或达达霉素，所需的菌血症4或更多天，研究受试者需要补充的头孢虫。它们还伴随着本地瓣膜感染性心内膜炎，骨髓炎或脑脓肿。患者分为两个队列。一组继续患有Ceftaroline加万古霉素或达摩霉素后菌血症分辨率（联合治疗组）。另一组接受了单独的万古霉素或达托霉素（单药治疗组）。所有涉及的疗法接受了6-8周的治疗。计算患者的PITT菌血症评分（PBS）和Charlson合并症指数（CCI）值。记录和比较菌血症，菌血症，30天休息，急性肾损伤和白细胞减少的治疗结果，进行了比较。培训总共包括30名患者的学习人群。 15名患者？分配给每个队列。组合治疗组的中位数PBS值为2，与单药治疗组中的1个相比。两组的中位数CCI得分为0.在两组中，在两组之间没有统计学显着差异。在两组中可以观察到上述治疗结果。愈合蛋白酶的组合蛋白菌血症，需要补充的头孢尔甘油，临床结果在规定的万古霉素或达达胺单独患者中没有差异在菌血症分辨率之后，与持续联合治疗的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号